YCM
SLXNW

Yakira Capital Management’s Silexion Therapeutics Warrant SLXNW Stock Holding History

Yakira Capital Management’s Portfolio SLXNW Stock Details SLXNW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-75,000
Closed -$5.74K – 241
2025
Q1 		$5.74K Hold
75,000
– – ﹤0.01% 165
2024
Q4 		$2.54K Hold
75,000
– – ﹤0.01% 212
2024
Q3 		$3.81K Buy
+75,000
New +$4.34K ﹤0.01% 212

Other funds holding SLXNW

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.02% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $4.82B AUM 24.91% 1-Year Est. Return
CS
Clear Street New York $24.6B AUM 56.25% 1-Year Est. Return
HP
Hartree Partners New York $467M AUM 66.71% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
SBLIC
Security Benefit Life Insurance Company Topeka, Kansas $182M AUM 31.21% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
KC
Kepos Capital New York $61.3M AUM 12.13% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Yakira Capital Management's SLXNW Position: Q2 2025 in Review

Yakira Capital Management sold out of Silexion Therapeutics Warrant (SLXNW) in Q2 2025, closing a stake of 75,000 shares — an estimated $5.74K sold.

Yakira Capital Management first reported a position in SLXNW in Q3 2024 and held it in 3 quarters. The position peaked at $5.74K in Q1 2025. 22 funds tracked by Wall St. Rank hold SLXNW as of Q2 2025.

  • Yakira Capital Management reported no remaining Silexion Therapeutics Warrant position as of Q2 2025 after selling out during the quarter.
  • Yakira Capital Management sold 75,000 Silexion Therapeutics Warrant shares in Q2 2025, an estimated $5.74K.
  • Yakira Capital Management first reported a position in Silexion Therapeutics Warrant in Q3 2024 and held it in 3 quarters.
  • Yakira Capital Management's Silexion Therapeutics Warrant position peaked at $5.74K in Q1 2025.
  • 22 funds tracked by Wall St. Rank held Silexion Therapeutics Warrant as of Q2 2025.

Based on Yakira Capital Management's 13F filing for Q2 2025, filed 13 Aug 2025.